Development of a Topical Polymeric Mucoadhesive Ocular Delivery System for Azithromycin

Bowman, Lyle M.; Si, Erwin; Pang, Joseph; Archibald, R. McL.; Friedlaender, Mitchell H.

doi:10.1089/jop.2008.0066

Cited by 51 publications

(41 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data suggest that in situ gel may play a major role in the pharmacokinetic behavior of 1% ATM. We compared our rabbit data with those of Bowman et al (2009), who performed PK studies of a 1% ATM polycarbophil-based ophthalmic delivery system (DuraSite) and two data show similar PK.…”

Section: In Vivo Resident Evaluationmentioning

confidence: 99%

New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system

2010

View full text Add to dashboard Cite

Section: In Vivo Resident Evaluationmentioning

confidence: 99%

New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system

2010

View full text Add to dashboard Cite

“…In ophthalmology, oral administration of Azithromycin has been shown effective for the treatment of trachoma. The treatment of ocular surface infections with topical Azithromycin appealing in medicine is restricted because of systemic exposure to the drug (14). Major topical formulation problems originate from the fact that Azithromycin is hydrophobic and rarely soluble in water at neutral pH (15).…”

Section: Introductionmentioning

confidence: 99%

A Novel Microemulsion System for Ocular Delivery of Azithromycin: Design, Characterization and Ex-Vivo Rabbit Corneal Permeability

Salimi

Panahi-Bazaz

2017

Jundishapur J Nat Pharm Prod

View full text Add to dashboard Cite

Background: The poor bioavailability of ophthalmic drops is mainly due to the rapid nasolacrimal drainage of the drug and very low permeability of corneal epithelium. Hence, there is an interest to find an effective system to improve drug permeability and bioavailability. Objectives: The aim of the present study was to design and characterize a novel microemulsion system as an ocular delivery system for Azithromycin and evaluate its physicochemical characteristics and rabbit corneal permeability in order to enhance the penetration of the drug. Methods: The prepared microemulsions (MEs) were assessed for their viscosity, pH, particle size, surface tension, DSC, stability, in vitro drug release, and corneal rabbit permeability. In this study, a full factorial design was employed with 3 variables at 2 levels for preparing 8 formulations and data analysis. Results:The results showed that the average droplet size of ME formulations was in the range of 6.78 to 26.65 nm while pH values were 5.1 to 5.7 and viscosity range was 115 -361 cps. Drug release profile revealed that 79.066% of the drug released in 24 hours of the experiment. The maximum and minimum percentages of drug permeated through rabbit cornea were observed in MEA-7 (12.87%) and MEA-2 (0.909%), respectively. All ME formulations with different compositions and properties significantly increased partitioning, flux, and permeability coefficient from rabbit cornea. Dapp and Papp parameters in MEA-1 and MEA-7 formulations were 0.00882 cm 2 h -1 and 2.391 cmh -1 , which were 17.65, 35.17 times higher than those of control (AZ suspension, 1%), respectively. The

show abstract

“…16 Furthermore, 1% azithromycin in DuraSite, a mucoadhesive vehicle, achieved high ocular surface tissue level. 17 Azithromycin's anti-inflammatory properties have been shown to be mediated by its ability to inhibit pro-inflammatory NF-kB activity in lung carcinoma cell line 6 and to suppress zymosan-stimulated production of proinflammatory cytokines in human corneal epithelial cells. 18 These data support the hypothesis that ocular surface disease whereby an inflammatory cascade mediated by activation of the NFkB pathway, such as pterygium, may also be inhibited and relieved by topical azithromycin.…”

Section: Discussionmentioning

confidence: 99%

Topical Azithromycin 1% in acute management of inflammatory pterygium

et al. 2011

View full text Add to dashboard Cite

The purpose of the article is to investigate the effects of topical azithromycin 1% (Azasite) in treating acute ocular inflammation related to long standing pterygium. A prospective interventional study of 8 consecutive cases with pterygium presenting to our University Eye Clinics over the period of one month with acute symptoms of red eye(s) and irritation. After patient education and receipt of consent to the study, patients were treated with topical azithromycin 1% (Azasite) twice a day for the first two days and once a day for the next 12 days. Anterior segment photo was taken before treatment and 3-day and/or 7-day after treatment in addition to eye examination.

show abstract

Development of a Topical Polymeric Mucoadhesive Ocular Delivery System for Azithromycin

Cited by 51 publications

References 24 publications

New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system

New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system

A Novel Microemulsion System for Ocular Delivery of Azithromycin: Design, Characterization and Ex-Vivo Rabbit Corneal Permeability

Topical Azithromycin 1% in acute management of inflammatory pterygium

Contact Info

Product

Resources

About